OncoAssure Ltd, an Irish medical diagnostic company, announced the publication of new data in the journal BJUI Compass that demonstrate the clinical validation of OncoAssure Prostate, a novel biopsy ...

A hydroablation device for benign prostatic hyperplasia showed promise as a potential treatment aid for early prostate cancer in a small Chinese study. The proportion of patients with detectable ...

The company is racing to advance its medical device for prostate cancer to a pivotal clinical study later this year. A Durham company wants to raise $10 million to advance its medical device to a ...

The commercial-stage medical device company it again has received exclusive distribution rights for Tulsa-Pro in Canada from Knight Therapeutics. Profound Medical develops and markets artificial ...

In an advancement for minimally invasive care, a first-ever procedure using two separate surgery robots was successfully completed. A urologist at the University of Texas (UT) Southwestern Medical ...

ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan). This will allow ...

Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the CAPItello-281 Phase ...

ANN ARBOR, Mich. - Chuck Single and Jack Cochrane have plenty in common. They both are 76-year-old prostate cancer survivors, Ann Arbor residents and retired engineers determined to fix problems they ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...